ESPR Esperion Therapeutics Inc

Esperion to Present at the CIBC World Markets Healthcare Conference ANN ARBOR, Mich., Nov. 10 /PRNewswire-FirstCall/ -- Esperion Therapeutics, Inc. , a biopharmaceutical company dedicated to the discovery, development and commercialization of therapies to improve the treatment of cardiovascular disease, today announced that Roger S. Newton, Ph.D., will present at the CIBC World Markets Healthcare Conference on Wednesday, November 12, 2003 in New York City. Dr. Newton is scheduled to speak at 2:30 p.m. (ET). Investors and others may access a live audio webcast of the presentation at http://www.esperion.com/ by first clicking the Investor Relations link and then clicking the Calendar link. A webcast replay of the Esperion presentation may be accessed until December 12, 2003 by first clicking the Investor Relations link and then clicking the Audio/Visual Archives link. Esperion Therapeutics Esperion Therapeutics, Inc. discovers and develops pharmaceutical products for the treatment of cardiovascular disease. Esperion intends to commercialize a novel class of drugs that focuses on a new treatment approach called "HDL Therapy," which is based on the Company's understanding of high- density lipoprotein, or HDL, function. HDL is the primary facilitator of the reverse lipid transport, or RLT, pathway by which excess cholesterol and other lipids are removed from artery walls and other tissues and are transported to the liver for elimination from the body. Esperion's goal is to develop drugs that exploit the beneficial functions of HDL within the RLT pathway. Esperion currently has four product candidates in clinical development. Esperion is listed on the Nasdaq National Market under the symbol "ESPR." Company Contact: Amy Cannon Manager, Corporate Communications Esperion Therapeutics, Inc. (734) 222-1801 DATASOURCE: Esperion Therapeutics, Inc. CONTACT: Amy Cannon, Manager, Corporate Communications of Esperion Therapeutics, Inc., +1-734-222-1801, Web site: http://www.esperion.com/

Copyright